Refine
Has Fulltext
- yes (27)
Is part of the Bibliography
- yes (27)
Document Type
- Journal article (23)
- Preprint (4)
Language
- English (27)
Keywords
- Positronen-Emissions-Tomografie (8)
- prostate cancer (8)
- theranostics (7)
- PET (5)
- PSMA (5)
- PSMA-RADS (4)
- RADS (4)
- neuroendocrine tumor (4)
- prostate-specific membrane antigen (4)
- 18F-DCFPyL (3)
- CXCR4 (3)
- PET/CT (3)
- Prostate Cancer (3)
- positron emission tomography (3)
- reporting and data system (3)
- somatostatin receptor (3)
- MRI (2)
- PRRT (2)
- PSMA-PET (2)
- Positron Emission Tomography (2)
- SSTR-RADS (2)
- Virchow Node (2)
- kidney (2)
- molecular imaging (2)
- norepinephrine transporter (2)
- peptide receptor radionuclide therapy (2)
- prostate-specific membrane antigen (PSMA) (2)
- radioligand therapy (2)
- somatostatin receptor (SSTR) (2)
- 18F-DCFPL (1)
- 18F-FDS (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATOC (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AI (1)
- CTCAE (1)
- DCGAN (1)
- GAN (1)
- GCA (1)
- Ganglia (1)
- Gleason score (1)
- Imaging pitfalls (1)
- MI-RADS (1)
- Magnetresonanztomografie (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- NET (1)
- PMR (1)
- PROMISE (1)
- PSMA-RADS-3A (1)
- PSMA-RADS-3B (1)
- PSMA-targeted PET (1)
- Pentixafor (1)
- Pitfall (1)
- Positron-Emission Tomography (1)
- Prostata (1)
- RLT (1)
- Radiofluorine (1)
- Radiotracer (1)
- SSTR (1)
- SSTR-PET (1)
- SUV (1)
- Sodium-Glucose Cotransporters (SGLTs) (1)
- T-shaped π-π stacking (1)
- Tracer (1)
- [18F]FDG PET/CT (1)
- [68Ga]DOTATOC (1)
- [68Ga]Pentixafor (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F (1)
- \(^{18}\)F-DCFPyL PET/CT (1)
- \(^{18}\)F-PSMA-1007 (1)
- \(^{68}\)Ga (1)
- artificial intelligence (1)
- cardiac innervation imaging (1)
- chemokine receptor (1)
- diabetes (1)
- ejection fraction (1)
- giant cell arteritis (1)
- glomerular filtration rate (1)
- hematotoxicity (1)
- inflammation (1)
- interobserver (1)
- interreader (1)
- left-ventricular function (1)
- machine learning (1)
- magnetic resonance imaging (1)
- meningioma (1)
- nephrology (1)
- nephrotoxicity (1)
- neuroblastoma (1)
- neuroendocrine neoplasia (1)
- neuroendocrine neoplasms (NEN) (1)
- neuroendocrine tumors (NET) (1)
- nonhuman primates (1)
- personalized medicine (1)
- polymyalgia rheumatica (1)
- prostate-specific antigen (1)
- quantification (1)
- radiotracer kinetics (1)
- rats (1)
- renal (1)
- renal function (1)
- renal imaging (1)
- reporting and data systems (1)
- solid tumors (1)
- split renal function (1)
- staging (1)
- standardization (1)
- standardized reporting (1)
- standardized reporting system (1)
- stroke (1)
- sympathetic nervous system (1)
- urology (1)
- vasculature (1)
- vasculitis (1)
- vestibular schwannoma (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (27)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (4)
- Medizinische Klinik und Poliklinik II (4)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Pathologisches Institut (2)
- Urologische Klinik und Poliklinik (2)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Medizinische Klinik und Poliklinik I (1)
- Neurochirurgische Klinik und Poliklinik (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (11)
Background. Mediating glucose absorption in the small intestine and renal clearance, sodium glucose cotransporters (SGLTs) have emerged as an attractive therapeutic target in diabetic patients. A substantial fraction of patients, however, only achieve inadequate glycemic control. Thus, we aimed to assess the potential of the SGLT-targeting PET radiotracer alpha-methyl-4-deoxy-4-[\(^{18}\)F]fluoro-D-glucopyranoside ([\(^{18}\)F]Me4FDG) as a noninvasive intestinal and renal biomarker of SGLT-mediated glucose transport. Methods. We investigated healthy rats using a dedicated small animal PET system. Dynamic imaging was conducted after administration of the reference radiotracer 2-deoxy-2-[\(^{18}\)F]fluoro-D-glucose ([\(^{18}\)F]FDG), or the SGLT-targeting agent, [\(^{18}\)F]Me4FDG either directly into the digestive tract (for assessing intestinal absorption) or via the tail vein (for evaluating kidney excretion). To confirm the specificity of [18F]Me4FDG and responsiveness to treatment, a subset of animals was also pretreated with the SGLT inhibitor phlorizin. In this regard, an intraintestinal route of administration was used to assess tracer absorption in the digestive tract, while for renal assessment, phlorizin was injected intravenously (IV). Results. Serving as reference, intestinal administration of [\(^{18}\)F]FDG led to slow absorption with retention of % of administered radioactivity at 15 min. [\(^{18}\)F]Me4FDG, however, was rapidly absorbed into the blood and cleared from the intestine within 15 min, leading to markedly lower tracer retention of % (). Intraintestinal phlorizin led to marked increase of [\(^{18}\)F]Me4FDG uptake (15 min, %; vs. untreated controls), supporting the notion that this PET agent can measure adequate SGLT inhibition in the digestive tract. In the kidneys, radiotracer was also sensitive to SGLT inhibition. After IV injection, [\(^{18}\)F]Me4FDG reabsorption in the renal cortex was significantly suppressed by phlorizin when compared to untreated animals (%ID/g at 60 min, vs. untreated controls, ; ). Conclusion. As a noninvasive read-out of the concurrent SGLT expression in both the digestive tract and the renal cortex, [\(^{18}\)F]Me4FDG PET may serve as a surrogate marker for treatment response to SGLT inhibition. As such, [\(^{18}\)F]Me4FDG may enable improvement in glycemic control in diabetes by PET-based monitoring strategies.